Starting in 2022, terms like radiation-dosimetry, radionuclide therapy, volume delineation, tumor retention, and tumor-to-background ratio became popular, highlighting the growing interest in FAP-targeted radioligand therapy. The gene discussed is FAP; the disease is neoplasm.